Studies with IBT Resistant and IBT-Dependent Mutants of Vaccinia Virus to Clarify the Mechanism of the Antipox Activity

  • Ehud Katz
  • Eva Margalith
  • Bela Winer
  • Haya Felix
  • Natan Goldblum
Part of the Chemotherapy book series (CT, volume 6)


The macromolecular events of vaccinia virus growth which are inhibted by isatin thiosemicarbazone (IBT) were followed. It was found that the maturation of the virus was blocked, although viral DNA, “early” polypeptides and most of the “late” viral polypeptides were synthesized in the presence of the drug. A similar maturational block occurred with the IBT— dependent mutant when growing in the absence of IBT.

Eight thiosemicarbazone-containing compounds which inhibited the growth of the wild-type strain and to which the IBT-resistant mutant showed resistance, supported the gorwth of the IBT-dependent mutant. This indicates that there is a correlation between the abilities of the compound to inhibit the wild-type growth and to enhance the growth of the IBT-dependent mutant. Two compounds which did not follow this rule and inhibited the growth of all three virus strains were found to inhibit virus growth by a mechanism different from that of IBT, which resulted in failure of the virus to synthesize its DNA. Their antiviral action is not attributed to the thiosemicarbazone component of the molecule but to the chemical structure attached.


Vaccinia Virus Dependent Mutant Virus Growth Structural Polypeptide General Virology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Appleyard, G., Hume, V.B.M. and Estwood, J.C.N. (1965). Annual N.Y. Academy of Sciences, 130, 92.CrossRefGoogle Scholar
  2. Bauer, D. (1955). British Journal of Experimental Pathology, 36, 105.PubMedGoogle Scholar
  3. Bauer, D. (1963). British Journal of Experimental Pathology, 44, 233.PubMedGoogle Scholar
  4. Bauer, D., Dumbell, K., Fox-Hulme, P., and Sadler, P. (1962)”. Bulletin W.H.O., 26, 727.Google Scholar
  5. Bauer, D. and Sadtir, P. (1959). Nature (London) 184, 1496.CrossRefGoogle Scholar
  6. Bauer, D. and Sadler, P., (1960). Lancet, 1, 1110.PubMedCrossRefGoogle Scholar
  7. Bauer, D. and Sadler, P. (1961). Nature (London), 190, 1167.CrossRefGoogle Scholar
  8. Easterbrook, K.B. (1961). Virology, 17, 245.CrossRefGoogle Scholar
  9. Hamre, E., Bernstein, J. and Donovick, R. (1950). Proceedings of the Society of Experimental Biology and Medicine, 73, 275.Google Scholar
  10. Hamre, D., Brownlee, L., and Donovick, R. (1951). Journal of Immunology, 67, 305.Google Scholar
  11. Holowczek, J.A. and Joklik, W.K. (1967). Virology, 33, 726.CrossRefGoogle Scholar
  12. Katz, E., Margalith, E. and Winer, B. (1973a). Journal of General Virology, 21, 477.PubMedCrossRefGoogle Scholar
  13. Katz, E., Margalith, E., Winer, B. and Goldblum, N. (1973b). Antimicrobial Agents and Chemotherapy, 4, 44.PubMedCrossRefGoogle Scholar
  14. Katz, E., Margalith, E., Winer, B. and Lazar, A. (1973c). Journal of General Virology, 21, 469.PubMedCrossRefGoogle Scholar
  15. Katz, E. and Moss, B. (1970a). Journal of Virology, 6, 717PubMedGoogle Scholar
  16. Katz, E. and Moss, B. (1970b). Proceedings of the National Academy of Sciences (USA), 66, 677.CrossRefGoogle Scholar
  17. Katz, E., Winder, B., Margalith, E. and Goldblum, N. (1973d). Journal of General Virology, 19, 161.PubMedCrossRefGoogle Scholar
  18. Minton, S., Officer, J. and Thompson, R. (1953). Journal of Immunology, 70, 222.Google Scholar
  19. Moss, B. (1968). Journal of Virology, 2, 1028.PubMedGoogle Scholar
  20. Moss, B. and Salzman, N.P. (1968). Journal of Virology, 2, 1016.PubMedGoogle Scholar
  21. Roily, H. and Winkelman, E. (1971). In: Advances of Antimicrobial and Antineoplastic Chemotherapy. Edited by M. Hejzlar, M. Semansky and S. Masak, p. 305.Google Scholar
  22. Salzman, N.P. and Sebring, E.D. (1967). Journal of Virology, 1, 16.PubMedGoogle Scholar
  23. Shatkin, A.J. (1963). Nature (London), 199, 357.CrossRefGoogle Scholar
  24. Singh, M. and Sugden, J.K. (1971). Pharmaceutic Acta Helvetiae, 46, 627.Google Scholar
  25. Thompson, R., Davis, J., Russell, P. and Hitchings, G. (1953b). Proceed-ints of the Society of Experimental Biology and Medicine, 84, 496.Google Scholar
  26. Thompson, R., Minton, S. Jr., Officer, J., and Hitchings, G. (1953a). Journal of Immunology, 70, 229.Google Scholar
  27. Thompson, R., Price, M. and Minton, S. (1951). Proceedings of the Society of Experimental Biology and Medicine, 78, 11.Google Scholar
  28. Tsunoda, A., Miyazaki, K., Aota, T., Matsumoto, S., Kumagai, K. and Ishada, N. (1971). Japanese Journal of Microbiology, 16, 61.Google Scholar
  29. Woodson, B. and Joklik, W.K. (1965). Proceedings of the National Academy of Sciences (USA), 54, 946.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1976

Authors and Affiliations

  • Ehud Katz
    • 1
  • Eva Margalith
    • 1
  • Bela Winer
    • 1
  • Haya Felix
    • 1
  • Natan Goldblum
    • 1
  1. 1.Chanock Centre for VirologyHebrew University-Hadassah Medical SchoolJerusalemIsrael

Personalised recommendations